CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

  • Current Quote
  • Stock Chart
$1.270.00 (0.00%)
Day High:$1.29
Day Low:$1.15
01/15/194:00 p.m. ET
Delayed at least 15 minutes.

Julia Balanova
Ph + 646 378 2936


Recent News

Dec 28, 2018CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
- Optimal dose determination from the PAC203 study expected in mid-2019 with topline data expected in the third quarter of 2019 - SEATTLE, Dec. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a meeting with the U.S. Food and Drug Administration (FDA). Topline efficacy an... 
Printer Friendly Version
Dec 18, 2018CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
- CTI receives input on key elements of new Phase 3 trial design for patients with myelofibrosis and severe thrombocytopenia - - Phase 3 trial of approximately 200 patients expected to begin enrollment in the third quarter of 2019 - SEATTLE, Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of ... 
Printer Friendly Version
Dec 13, 2018CTI BioPharma Announces Restructuring Plan
- Fifty percent reduction in workforce expected to improve efficiencies and preserve capital for pacritinib development - SEATTLE, Dec. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of the total number of the Company's employees. Cost savings of approximately $20 million prima... 
Printer Friendly Version


There are currently no events scheduled.


Download Documentation CTI BioPharma Corporate Presentation
Get help downloading or viewing the above file types
Data provided by Nasdaq. Minimum 15 minutes delayed.